Lumvoa™ — Veligrotug Infusion
For Active & Chronic Thyroid Eye Disease
Lumvoa (veligrotug-vvze) is the second FDA-approved medical therapy targeting the underlying biology of Thyroid Eye Disease, and the first with pivotal data in both the active and chronic phases. In its phase-3 trials it produced a ≥2 mm reduction in proptosis (bulging eyes) in 70% of patients with active disease — over a shorter 5-infusion course than the first-generation option — while significantly improving double vision and inflammation.
What Is Lumvoa?
Lumvoa (generic name: veligrotug) is a full antagonist monoclonal antibody to the IGF-1 receptor (IGF-1R), developed by Viridian Therapeutics and approved by the FDA in June 2026 for the treatment of Thyroid Eye Disease (TED), also called Graves' ophthalmopathy. Like teprotumumab (Tepezza), it is given as an intravenous (IV) infusion in an outpatient infusion center or physician's office, and it is approved for thyroid eye disease regardless of disease activity or duration.
What sets Lumvoa apart is that its pivotal program studied both recent-onset (active) TED and long-standing (chronic) TED — the latter a group with historically few non-surgical options. It reaches its treatment course in about 12 weeks (5 infusions), compared with the 24-week, 8-infusion teprotumumab schedule.
ASOPRS fellowship-trained oculoplastic surgeons are uniquely qualified to manage Thyroid Eye Disease across its full natural history — from monitoring the active inflammatory phase and administering IGF-1R therapy, through surgical rehabilitation when the disease stabilizes.
How It Works
The hallmark of TED is activation of orbital fibroblasts — connective tissue cells within the orbit — by two key cell-surface receptors: the thyroid-stimulating hormone receptor (TSHR) and the insulin-like growth factor-1 receptor (IGF-1R). When autoantibodies bind these receptors, fibroblasts proliferate, produce excess hyaluronic acid, and differentiate into fat cells, expanding orbital volume. The result is proptosis, lid retraction, double vision, and orbital pain.